Swiss National Bank lifted its holdings in shares of Editas Medicine Inc (NASDAQ:EDIT) by 11.7% during the 4th quarter, HoldingsChannel reports. The firm owned 44,800 shares of the company’s stock after purchasing an additional 4,700 shares during the quarter. Swiss National Bank’s holdings in Editas Medicine were worth $1,377,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the stock. Global Thematic Partners LLC boosted its position in shares of Editas Medicine by 8.7% during the 4th quarter. Global Thematic Partners LLC now owns 614,052 shares of the company’s stock valued at $18,869,000 after purchasing an additional 49,011 shares in the last quarter. State Street Corp boosted its position in shares of Editas Medicine by 305.4% during the 2nd quarter. State Street Corp now owns 537,640 shares of the company’s stock valued at $9,022,000 after purchasing an additional 405,022 shares in the last quarter. Ark Investment Management LLC boosted its position in shares of Editas Medicine by 121.9% during the 2nd quarter. Ark Investment Management LLC now owns 510,187 shares of the company’s stock valued at $8,561,000 after purchasing an additional 280,265 shares in the last quarter. Northern Trust Corp boosted its position in shares of Editas Medicine by 245.9% during the 2nd quarter. Northern Trust Corp now owns 373,149 shares of the company’s stock valued at $6,261,000 after purchasing an additional 265,273 shares in the last quarter. Finally, American Century Companies Inc. bought a new stake in shares of Editas Medicine during the 3rd quarter valued at about $7,497,000. Institutional investors own 72.40% of the company’s stock.

How to Become a New Pot Stock Millionaire

EDIT has been the topic of several research analyst reports. BidaskClub upgraded Editas Medicine from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. JMP Securities upped their target price on Editas Medicine from $40.00 to $67.00 and gave the company an “outperform” rating in a research report on Wednesday, March 7th. ValuEngine lowered Editas Medicine from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Zacks Investment Research lowered Editas Medicine from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Finally, SunTrust Banks raised Editas Medicine from a “hold” rating to a “buy” rating and upped their price target for the stock from $17.00 to $45.00 in a research note on Tuesday, January 23rd. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $37.88.

In other news, insider Katrine Bosley sold 9,134 shares of the stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $45.00, for a total value of $411,030.00. Following the completion of the sale, the insider now directly owns 1,318,631 shares of the company’s stock, valued at $59,338,395. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Andrew A. F. Hack sold 5,000 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $24.31, for a total value of $121,550.00. Following the completion of the sale, the chief financial officer now directly owns 5,000 shares of the company’s stock, valued at $121,550. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 101,782 shares of company stock worth $3,514,684. 19.40% of the stock is owned by company insiders.

Editas Medicine Inc (NASDAQ EDIT) opened at $41.42 on Wednesday. Editas Medicine Inc has a 52 week low of $13.12 and a 52 week high of $45.02. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.05 and a quick ratio of 9.05.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings results on Tuesday, March 6th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.09). Editas Medicine had a negative return on equity of 61.92% and a negative net margin of 876.49%. The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $4.25 million. During the same period last year, the company posted ($1.10) earnings per share. The firm’s quarterly revenue was up 311.1% compared to the same quarter last year. sell-side analysts predict that Editas Medicine Inc will post -3.23 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was originally published by Daily Political and is the property of of Daily Political. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2018/03/14/editas-medicine-inc-edit-shares-bought-by-swiss-national-bank.html.

About Editas Medicine

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine Inc (NASDAQ:EDIT).

Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.